Background: Heat shock A1B, also known as HSP70kDa protein 1B, encodes a 70kDa heat shock protein which is a member of the heat shock protein 70 family. HspA1B is a critical gene which related to many type of diseases by involving in the ubiquitin-proteasome pathway. However, the correlations of HspA1B to prognosis and tumor-infiltrating lymphocytes in different cancers remain unclear. Methods: HspA1B expression was evaluated on the Oncomine database and Tumor Immune Estimation Resource (TIMER) site. We analyzed the influence of HspA1B on clinical prognosis using Kaplan-Meier plotter, the PrognoScan database and Gene Expression Profiling Interactive Analysis (GEPIA). The correlations between HspA1B and cancer immune infiltrates was investigated via TIMER. In addition, correlations between HspA1B expression and gene marker sets of immune infiltrates were analyzed by TIMER and GEPIA. Results: Three cohorts (GSE9195, GSE9893, GSE3494-GPL96)) of breast cancer patients showed that high HspA1B expression was associated with poorer overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS). In addition, high HspA1B expression was significantly correlated with poor OS and progression-free survival (PFS) in bladder cancer, brain cancer and skin cancer. Moreover, HspA1B significantly impacts the prognosis of diverse cancers via The Cancer Genome Atlas (TCGA). HspA1B expression was positively correlated with infiltrating levels of CD4+ T and CD8+ T cells, macrophages, neutrophils, and dendritic cells (DCs) indifferent subtypes of Breast cancer. HspA1B expression showed strong correlations with diverse immune marker sets in BRCA-Luminal. Conclusions: Our findings suggest that HspA1B is correlated with prognosis and immune infiltrating levels of, including those of CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and DCs in multiple cancers, especially in colon and gastric cancer patients. In addition, HspA1B expression potentially contributes to regulation of tumor-associated macrophages (TAMs), DCs, T cell exhaustion and Tregs in colon and gastric cancer. These findings suggest that HspA1B can be used as a prognostic biomarker for determining prognosis and immune infiltration in BRCA-Luminal subtype.
INTRODUCTION
Breast Cancer is the most common and the most-studied malignancy among worldwide, and metastasis is an important biological feature that leads to a poor prognosis [1] . Researchers have made great strides in the treatment of some types of breast cancer, but the battle continues on many fronts. Immune-related mechanisms play an important role in breast cancer, and immunotherapy are considered a promising direction for the treatment of breast cancers [2, 3] , whereby scientists are attempting to harness the body's own immune system to fight and prevent malignancies [4] . Immunotherapy, such as PD-1, PD-L1 and cytotoxic T lymphocyte associated antigen 4 (CTLA4) inhibitors, has demonstrated promising anti-tumor effects in NSCLC and melanoma [4] [5] [6] . However, current immunotherapies, such as anti-CTLA4 [7] [8] [9] showed poor clinical efficacy in breast cancers, blockade of PD-1 or PD-L1 shows antitumor activity in some subsets of breast cancer patients [3] . Additionally, an increasing number of studies have found that the tumor-infiltrating lymphocytes (TIL) play an essential role in mediating response to chemotherapy and improving clinical outcomes of various cancer types [10, 11] , such as tumor associated macrophages (TAMs) [12] [13] [14] and tumor-infiltrating neutrophils (TINs), they also affect the prognosis [15] [16] [17] [18] . Therefore, there is an urgent need for the elucidation of the immunophenotypes of tumor-immune interactions and identification of novel immune-related therapeutic targets in breast cancers.
The heat shock protein family member 1B (HspA1B), also known as HSP70kDa protein 1B, is a protein encoding-gene located on chromosome 6, which was first reported in 1999 [19] . This intronless gene encodes a 70kDa heat shock protein which is a member of the heat shock protein 70 family [20] . Compared to the other human heat shock protein family were discovered in 1980s, the discovery of HspA1B was nearly twenty years later [21, 22] . HspA1B is expressed in many cell types and organs [26] [27] [28] , it is a stress-inducible molecular chaperone with key roles that involve polypeptides refolding and degradation. It is also involved in the ubiquitin-proteasome pathway through interaction with the AU-rich element RNA-binding protein 1. The gene is located in the major histocompatibility complex class III region, in a cluster with two closely related genes which encode similar proteins [23, 24] . In conjunction with other heat shock proteins (eg. Hsp90), Hsp70 could form a complex to stabilize existing proteins against aggregation and mediates the folding of newly translated proteins in the cytosol and in organelles [25] [26] [27] . Moreover, this cochaperones complex can interact within the ligand binding domain of the glucocorticoid receptor (GR) to stabilize a specific conformational [28, 29] . Unlike other steroid hormone receptors, glucocorticoid receptor (GR) is not considered an oncogene, but it paly important role in various types of cancer. Glucocorticoids have the potential to play multiple roles in the regulation of breast cancers including their control of cellular differentiation, apoptosis and proliferation [30] . Moreover, glucocorticoids (GCs) work through GR to arrest growth and induce apoptosis in lymphoid tissue to contribute tumor invasion and metastasis [31] . All these imply that Hsp70 members play an important role in cancer. Previous studies indicate that Hsp70A1A is involved in pancreatic cancer and hepatocellular carcinoma [32, 33] , but the relationship between Hsp70A1B and tumor progression and the mechanism which involved in is still not well defined. Our previous research found that Single cell RNA sequencing of T cells confirmed that HspA1B was up regulated in activated CD8+ T and Treg cells and represses CD8+ T cell functions in vitro. These findings suggest that HspA1B has multifaceted functional roles in Treg cells and tumor infiltrating lymphocytes. However, the underlying functions and mechanisms of HspA1B in tumor progression and tumor immunology is still unclear. In this present study, we comprehensively analyzed HspA1B expression and correlation with prognosis of cancer patients in databases such as Oncomine, PrognoScan, and Kaplan-Meier plotter. Moreover, we investigated the correlation of HspA1B with tumor-infiltrating immune cells in the different tumor microenvironments via Tumor Immune Estimation Resource (TIMER). The findings in this report shed light on the important role of HspA1B in colorectal and gastric cancers as well as provide a potential relationship and an underlying mechanism between HspA1B and tumor-immune interactions.
based on RNA-Seq and Affymetrix microarrays. Interestingly, the poor prognosis in Liver cancer, Kidney renal papillary cell carcinoma, Lung adenocarcinoma, Sarcoma, Thymoma was shown to correlate with higher HspA1B expression ( Figures  2A-E and Supplementary Figure 1) . In addition to RNA-Seq of HspA1B in the Kaplan-Meier plotter databases, the microarray analysis data also used to analyze the prognostic potential of HspA1B in different cancers (Breast Cancer, Gastric Cancer, Lung Cancer, Ovarian Cancer) via Kaplan-Meier plotter. The poor prognosis in Breast Cancer while a better prognosis in Gastric Cancer was shown to correlate with higher HspA1B expression ( Figures 2H,I and Supplementary Figure 1 ) In addition to microarray analysis and RNA-Seq dataset of HspA1b in the PrognoScan and Kaplan-Meier plotter databases, the RNA sequencing data in TCGA were also used to analyze the prognostic potential of HspA1b in different cancers via GEPIA. We analyzed relationships between HspA1b expression and prognostic values in 33 types of cancer HspA1B expression significantly impacts prognosis in 6 type cancers, including KIRP(Kidney renal papillary cell carcinoma), LAML(Acute Myeloid Leukemia),
LGG (Brain Lower Grade Glioma), LIHC, MESO (Mesothelioma) and SKCM and shows a better OS in KIRC(Kidney renal clear cell carcinoma) (Figures 2 j-o). High HspA1B expression levels were associated with poorer prognosis of DFS in SKCM but has less influence on OS. These results confirmed the prognostic value of HspA1B in some specific types of cancers and that increased and decreased HspA1B expression have different prognostic value depending on the type of cancer.
High HspA1B Expression Impacts the Prognosis of Liver Cancer, Ovarian Cancer and Breast Cancer in Patients
To better understand the relevance and underlying mechanisms of HspA1B expression in cancer, we investigated the relationship between the HspA1B expression and clinical characteristics of liver cancer patients in the Kaplan-Meier plotter databases. Overexpression of HspA1B was associated with worse OS and PFS in female patients, race as well as different types of classification and differentiation (P < 0.05). Specifically, high HspA1B mRNA expression was correlated with worse OS in stage 3 to 4 and worse PFS in stage 1 to 2 of Liver cancer patients respectively but was not associated with OS and PFS of other stages. (Table 1) . Since HspA1B showed gender correlation, we checked the female-specific cancers in the database (SI-Fig1). We found that high HspA1B Expression was associated with worse OS and PFS in different Intrinsic subtype of breast cancer. High HspA1B Expression was associated with poor OS and PFS in Luminal A subtype, but no significant difference in luminal B and HER2+ subtype. High HspA1B mRNA expression was correlated with worse OS and PFS in Endometrioid type and worse PFS in Serous type of Ovarian cancer patients respectively but was not associated with OS and PFS of stages, grades and TP53 mutation( Table 2 ).. Supplementary Figure 2 
HspA1B Expression Is Correlated With Immune Infiltration Level in Breast Cancers
Tumor-infiltrating lymphocytes are an independent predictor of sentinel lymph node status and survival in cancers. Therefore, we investigated whether HspA1B expression was correlated with immune infiltration levels in different types of cancer. We assessed the correlations of HspA1B expression with immune infiltration levels in 34 cancer types from TIMER. The results show that HspA1B expression has significant correlations with tumor purity in 8 types (DLBC, ESCA, HNSC, LGG, LUAD, LUSC, PAAD, STAD) of cancer and significant correlations with B cell infiltration levels in 11 types of cancers (COAD, ESCA, KICH, LGG, LUAD, LUSC, PRAD, STAD, TGCT, THYM, UVM) (SI Fig3). In addition, HspA1B expression has significant correlations with infiltrating levels of CD8+ T cells in 13 types of cancer (COAD, DLBC, LUSC, PAAD, PRAD, READ, SARC, SKCM, SKCM−Primary, SKCM−Metastasis, THYM, UCS, UVM), CD4+ T cells in 11 types of cancer (COAD, ESCA, HNSC, LGG, LUAD, LUSC, PRAD, STAD, THCA, THYM, UCEC), macrophages in 14 types of cancer (BLCA, COAD, DLBC, KIRC, LGG, LUAD, LUSC, OV, PAAD, PRAD, SKCM, STAD, TGCT, THYM), neutrophils in 17 types of cancer (ACC, BLCA, COAD, HNSC, KIRC, LGG, LUAD, LUSC, PCPG, READ, SKCM, SKCM−Primary, SKCM−Metastasis, TGCT, THCA, THYM, UCEC), and dendritic cells in 17 types of cancer (BLCA, ESCA, HNSC, KIRC, LGG, LIHC, LUAD, LUSC, PAAD, PRAD, SKCM, SKCM−Primary, STAD, TGCT, THCA, THYM, UVM) ( Supplementary Figure 3) . Given the association of HspA1b expression with immune infiltration level in diverse types of cancer, we next determined the distinct types of cancers in which HspA1b was associated with prognosis and immune infiltration. Tumor purity is an important factor that influences the analysis of immune infiltration in clinical tumor samples by genomic approaches, and TIMER and GEPIA have most of the homologous data from TCGA. Therefore, we selected the cancer types in which HspA1b expression levels have a significant negative correlation with tumor purity in TIMER and a significant correlation with prognosis in GEPIA. Interestingly, we found that HspA1B expression level correlate with poorer prognosis and high immune infiltration in KIRP, LAML, LGG, LIHC, MESO, SKCM and different Breast Cancers subtypes. HspA1B expression level has significant positive correlations with infiltrating levels of CD4+ T cells, macrophages, neutrophils and DCs in LGG (Fig3, SI-Fig2 AC). Similarly, there were positive correlations with infiltrating levels of CD8+ T cells, macrophages, neutrophils and DCs in SKCM (Fig3, SI-Fig2 AY). More Interestingly, the correlation with macrophages and DCs are different pattern in Primary and Metastasis subtypes of SKCM (Fig3). These findings strongly suggest that HspA1b plays a specific role in immune infiltration in LGG and SKCM cancers. What attracted our attention is the HspA1B Expression Is Correlated With Immune Infiltration Level in different Breast Cancers subtypes ( Fig 2H, Fig 4) . There were positive correlations with infiltrating levels of B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils and DCs in BRCA (Fig4 A), but the correlations with infiltrating levels of immune cells are demonstrated different pattern between Basal, Her2 and Luminal subtypes (Fig4 B-D). HspA1B expression level has significant positive correlations with infiltrating levels of B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils and DCs in Luminal subtypes (Fig4 D), but none of them is correlated with Basal and Her2 subtypes of BRCA (Fig4 B, C). These findings strongly suggest that HspA1B plays a specific role in immune infiltration in different subtypes of BRCA.
Correlation Analysis Between HspA1B Expression and Immune Marker Sets
To investigate the relationship between HspA1B and the diverse immune infiltrating cells, we focused on the correlations between HspA1B and immune marker sets of various immune cells of LGG, SKCM and BRCA in the TIMER and GEPIA databases. We analyzed the correlations between HspA1B expression and immune marker genes of different immune cells, included CD8+ T cells, T cells (general), B cells, monocytes, TAMs, M1 and M2 macrophages, neutrophils, NK cells and DCs in different subtypes of BRCA, using Adrenocortical Carcinoma (AAC) as the control ( Table 5 ). We also analyzed the different functional T cells, such as Th1 cells, Th2 cells, Tfh cells, Th17 cells, and Tregs, as well as exhausted T cells. After the correlation adjustment by purity, the results revealed the HspA1B expression level was significantly correlated with most immune marker sets of various immune cells and different T cells in different subtypes of BRCA. However, none of these gene markers was significantly correlated with the HspA1B expression level in AAC ( Fig  5) .
DISSCUSION
HSP70 is a stress-inducible molecular chaperone with key roles that involve polypeptides refolding and degradation. Although HspA1B has not been extensively studied, it is known that HspA1B is upregulated in activated Treg and CD8+ lymphocytes. In addition, it suppresses CD8+ functions in lung, colorectal and hepatocellular cancers. Here, we report that variations in HspA1B expression level correlate to prognosis in different types of cancer. High expression level of HspA1B correlates with a poorer prognosis in four type cancers, including Bladder Cancer, Brain cancer, Breast cancer and Skin cancer. Furthermore, our analyses show that in different subtypes of breast cancers immune infiltration levels and diverse immune marker sets are correlated with levels of HspA1B expression. Thus, our study provides insights in understanding the potential role of HspA1B in tumor immunology and its use as a cancer biomarker for different subtypes of breast cancer.
In this study, we examined the expression levels of HspA1B and systematic prognostic landscape in different types of cancers using independent datasets in Oncomine and 33 type cancers of TCGA data in GEPIA. The differential expression of HspA1B between cancer and normal tissues was observed in many types of cancer. Based on the Oncomine database, we found that HspA1B, compared to normal tissues, was highly expressed in Gastric, Head and neck, Pancreatic Cancer, Leukemia, Lymphoma and Melanoma, while some data sets showed that HspA1B has a lower level of expression in Head and neck, Lung cancer, Melanoma and Sarcoma ( Figure  1A ). However, analysis of the TCGA data showed that HspA1B expression was higher in BLCA, BRCA, CHOL, COAD, ESCA, LIHC, LUAD, LUSC, PRAD, READ, STAD, UCEC, but lower expression in HNSC, KIRC, THCA, compared with normal adjacent tissues ( Figure 1B ). The discrepancies in levels of HspA1B expression in different cancer types in different databases may be a reflection in data collection approaches and underlying mechanisms pertinent to different biological properties. Analysis of the TCGA database revealed that increased HspA1B. expression correlated with poor prognosis in most tumor types (KIRP, LAML, LGG, LIHC, MESO and SKCM). KIRC was exception where high levels of HspA1B expression showed a better prognosis.
Furthermore, analysis of data from PrognoScan showed high level of HspA1B expression was correlated with poor prognosis of OS in Brain cancer, Breast cancer and Skin cancer (Figures 2). Kaplan-Meier Plotter also showed a high HspA1B expression correlated with high hazard ratio (HR) for poor overall survival (OS) and progress free survival (PFS) of liver, Kidney renal papillary cell carcinoma, Lung adenocarcinoma, Sarcoma, Thymoma and Breast Cancer (Figures 2). In addition, high level of HspA1B expression was shown to be correlated with poor OS and PFS in SKCM, with poor OS and DFS, DMFS in Breast Cancer and with poor OS in two datasets (GSE4271-GPL96, MGH-glioma) of Brain Cancer. Together these findings strongly suggest that HspA1b is a prognostic biomarker in SKCM, LGG, and Breast Cancer.
Another important aspect of this study is that HspA1B expression is correlated with diverse immune infiltration levels in cancer, especially in SKCM, LGG, and Breast Cancer. Our results demonstrate that there is a significantly positive correlations between infiltration level of CD8+ T, CD4+ T cells, macrophages, neutrophils and DCs and HspA1B expression in LUSC, THYM and BRCA ( Figures 3A,C) . Interestingly, the correlation of the infiltration level are different in there subtypes of the breast cancer. The correlation between HspA1B expression and the marker genes of immune cells implicate the role of HspA1B in regulating tumor immunology in these types of cancers.
Firstly, gene markers of M1 macrophages such as NOS2 and IRF5 did not show correlations with HspA1B expression, whereas M2 macrophage markers such as CD163, VSIG4, and MS4A4A showed strong correlations in BRCA and BRCA-Luminal (Tables 2, 3 ). These results reveal the potential regulating role of HspA1B in polarization of tumor-associated macrophages (TAM), especially in BRCA-Luminal. Secondly, our results indicated that HspA1B has the potential to activate Tregs and induce T cell exhaustion. The increase in HspA1B expression positively correlates with the expression of Treg and T cell exhaustion markers (FOXP3, CCR8, STAT5B, TGFB1, PD-1, CTLA4, LAG3, HAVCR2 and GZMB in BRCA and BRCA-Luminal (Table 3) . HAVCR2, a crucial surface protein on exhausted T cells (38) , is highly correlated with HspA1B expression in BRCA and BRCA-Luminal, and demonstrated different correlations pattern in another two BRCA subtypes (BRCA-Basal and BRCA-Her+). Furthermore, different correlations patterns can be found between HspA1B expression and the regulation of several markers of T helper cells (Th1, Th2, Tfh, and Th17) in three breast cancer subtype patterns. These correlations could be indicative of a potential mechanism where HspA1B regulates T cell functions in BRCA and BRCA-Luminal other than BRCA-Basal and BRCA-Her+ subtypes. Together these findings suggest that the HspA1B plays an important role in recruitment and regulation of immune infiltrating cells in BRCA and BRCA-Luminal.
Heat shock proteins (HSPs) are highly conserved proteins throughout evolution process, and the HSP70 is a stress-inducible molecular chaperone with key roles that involve polypeptides refolding and degradation. All members of the Hsp70 family consist of two major functional domains: an N-terminal nucleotide/ATPase binding domain (NBD) and a C-terminal substrate-binding domain (SBD) [44] [45] [46] . Hsp70 and Hsp90 are the two main types of human heat shock proteins, both of which play an important role in tumorigenesis, development, invasion, metastasis, and so on. Hsp90 can be used as anti-cancer targets. Significant tumor suppression effects have been demonstrated by some groups by inhibiting the expression of Hsp90 in tumor cells [47] [48] [49] [50] .
The BAG-1 gene (Bcl-2 binding anti-apoptotic gene 1) is an important component of the BAG gene family and act as a anti-apoptotic gene. It encodes the multifunctional protein BAG-1 protein, which acts against a variety of cytokines and inhibits tumor cell apoptosis. The anti-apoptotic effect of BAG family proteins can be regulated by the interaction of Hsc70/Hsp70 with the BAG domain. BAG family proteins can act as co-chaperones, indirectly regulating Hsc70/Hsp70-mediated protein overlap and protein degradation, and could cause elevated levels of intracellular oncoproteins [51, 52] . BAG-1 interacts with the anti-apoptotic protein Bcl-2 [52] , causing tumor growth, and this effect is mediated by Hsc70/Hsp70 complex [53, 54] . The BAG-1 isoform is also highly expressed in human breast cancer [55] . It has been confirmed by immunochromatographic experiments [56] that BAG-1 was highly expressed in 147 (90%) of 160 breast cancer patients, mostly in the cytoplasm, and only a few were expressed in the nucleus. At the same time, studies have shown that [57] , BAG-1 is 77.1% high in 140 patients with breast sarcoma. Multivariate analysis of the above results indicated that BAG-1 expression was significantly associated with tumor recovery and survival and survival. So all these indicated that HspA1B could be related to the prognosis of breast cancer closely.
Nowadays, more and more Hsp90 inhibitors has been discovery and designed as anti-tumor reagents, among which Tanespimycin (17-AAG) has entered the phase II clinical trial stage [58] [59] [60] . Ganetespib (STA-9090) and AT13387 are also high efficiency anti-tumor chemical by inhibiting Hsp90. However, whether Hsp70 could work as an anti-tumor target is not well defined, and there are not such many inhibitors as HSP90 under study. There is only one Hsp70 inhibitor design-VER-155008, however the IC50 is 0.5 μ M, it is not a good lead for pharmaceutical production.
HSP70 is regulated by the cell cycle and is kept in a low level in normal cells. But in tumor cells, the expression level is increased due to the stimulation by mutant or abnormal proteins [61] . Some research showed that in tumor microenvironment, Hsp70 /Hsp70 complex (HSP70 /HSP70-PCs) plays a complex and important roles. On one side, it could activate immune cells, activate cellular immunity to kill tumor cells. On the other hand, it may increase the immune escape ability of tumor cells through signaling pathways, in this way to suppress the tumor killing. HSP70/HSP70-PCs could promote epithelial mesenchymal transition (EMT) process and the migration and invasion of tumor cells in HCC. HSP70 /HSP70-PCs could promote the proliferation of the tumor cells by activating TLR2 and TLR4 firstly and then followed by activating JNK/MAPK pathway [62] [63] [64] . Also, the expression of HSP70 is high in hepatitis C-associated HCC, suggesting that HSP70 might be a molecular target for hepatitis C-associated HCC therapy [65] . It has been reported that estrogen could induce the phosphorylation of HSP by active PI3K/Akt signaling pathway [66] . So we believe that Hsp70 might change the prognosis of breast cancer by interacting with estrogen and the immune microenvironment of cancer.
CONCLUSIONS
In this study, we provided possible mechanisms which explains why HspA1B expression correlates with immune infiltration and poor prognosis in some cancer types, especially in breast cancer. Therefore, interactions between HspA1B and TME (immune cells and estrogen) could be a potential mechanism for the correlation of HspA1B expression with immune infiltration and poor prognosis in BRCE-Luminal subtype. 
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Bold values indicate P < 0.05. 
